Handelsavisen has updated its investment thesis on Vivani Medical Inc (VANI.O) following an internal audit of sector classification data.
The revision stems from a sector-fix batch process that corrected contamination in the company’s GICS direct path, prompting a re-analysis of the firm’s positioning and fundamentals.
The updated assessment maintains a composite score of 30 out of 100 in Handelsavisen’s proprietary analysis, reflecting persistent concerns over the company’s financial health and market position.
The low score underscores structural weaknesses that remain unresolved despite the data correction, suggesting limited near-term upside for investors.
This internal adjustment highlights the importance of accurate sector tagging in equity research, particularly for smaller-cap firms where misclassification can distort peer comparisons and valuation metrics.
The re-analysis ensures that Vivani Medical is now evaluated against the correct industry benchmarks, providing a more reliable basis for investment decisions.